logo-loader

Full interview: Kazia Therapeutics presents new data from Cantrixil Phase 1 Study in Ovarian Cancer at global conference

Published: 12:59 01 Oct 2019 AEST

Kazia Therapeutics Ltd - Kazia Therapeutics presents new data from Cantrixil Phase 1 Study in Ovarian Cancer at global conference

Kazia Therapeutics Limited (ASX:KZA) chief executive officer Dr James Garner updates Proactive on the company’s presentation of new data from the Cantrixil Phase 1 Study in Ovarian Cancer, at the European Society for Medical Oncology (ESMO) in Barcelona, Spain.

The CEO also spoke about Kazia winning a award at the inaugural ANZLF Trans-Tasman Innovation & Growth Awards, with the $20,000 prize presented by New Zealand Prime Minister Jacinda Ardern. 

In other milestones, Dr Garner discussed important work Kazia is doing with the US-based St Jude’s Children’s Research Hospital into a rare and deadly form of childhood brain cancer, and how the World Health Organisation has selected a provisional name for the company’s lead drug GDC-0084.

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

6 hours, 11 minutes ago